PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.40%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-20.40%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-19.78%
Negative net income growth while AVXL stands at 10.36%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
12.20%
EPS growth 1.25-1.5x AVXL's 8.33%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
12.20%
Diluted EPS growth 1.25-1.5x AVXL's 8.33%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
35.62%
Share count expansion well above AVXL's 1.29%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
35.62%
Diluted share count expanding well above AVXL's 1.29%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-10.71%
Negative OCF growth while AVXL is at 23.16%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-10.88%
Negative FCF growth while AVXL is at 23.16%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-812.85%
Negative 10Y OCF/share CAGR while AVXL stands at 67.06%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
87.84%
5Y OCF/share CAGR above 1.5x AVXL's 8.65%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
86.67%
3Y OCF/share CAGR above 1.5x AVXL's 4.50%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-1279.04%
Negative 10Y net income/share CAGR while AVXL is at 70.46%. Joel Greenblatt sees a major red flag in long-term profit erosion.
88.03%
5Y net income/share CAGR above 1.5x AVXL's 50.58%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
86.27%
Positive short-term CAGR while AVXL is negative. John Neff would see a clear advantage in near-term profit trajectory.
1371.24%
10Y equity/share CAGR above 1.5x AVXL's 130.37%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-83.09%
Negative 5Y equity/share growth while AVXL is at 13.51%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-60.87%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.71%
Negative asset growth while AVXL invests at 1.97%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-34.03%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-19.69%
We’re deleveraging while AVXL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
7.98%
R&D growth drastically higher vs. AVXL's 11.10%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
58.15%
We expand SG&A while AVXL cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.